{"name":"Biocity Biopharmaceutics Co., Ltd.","slug":"biocity-biopharmaceutics-co-ltd","ticker":"","exchange":"","domain":"biocitybiopharmaceutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo matched to SC0062","genericName":"Placebo matched to SC0062","slug":"placebo-matched-to-sc0062","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Placebo matched to SC0062","genericName":"Placebo matched to SC0062","slug":"placebo-matched-to-sc0062","phase":"phase_3","mechanism":"This is a placebo control formulation matched to SC0062, containing no active pharmaceutical ingredient.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPZDg1Z01CSUR6V0pPTkdnYmFaNEE3NzA1US03VWZJLTg3Y05FTWVpZ0MwS2xaVEFhSXFLMElZbmtrdzUxbEpFTHdiNzBKZDN6enJiZWdLV2tNQjRPaU5qcVJmN0luRlFFNEF1R01nWXVreTl5SUszaDgtNkVtcUx5WFhzUkcyeWk2M1ZrRWUxcERobWZVOTkxTmdadi05Zw?oc=5","date":"2026-03-11","type":"trial","source":"openPR.com","summary":"Advanced Liver Cancer Clinical Trial Pipeline Shows Potential - openPR.com","headline":"Advanced Liver Cancer Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOY3UwTFY2ZGI5ZXJNUEJVZ3o0ZThCdTFOWm5uN0t4QU0xOUVrOU8ySndNOER3Y2VhVWlDZUJZcWxlc3FpQUFzNERwdTEzdjJyTllyalNuVmwzbEJzX1RUN3hpUDZWZkg0X3VxZmRfYlhhS1M5VDZrLWRxZEJBdFkzSlpFU2NJY2VnRTBGMl9kT2l1aURLbXhLbGtfQXFqWU0wWllEV2RkdkN0TndsbE1iVzZWX1lReXFYZkNTaVJuQUJlXzFQSi1HNjA0Ti1kaVNDcUE4QXBJZU1OUVV3Znk3aHZjdmxMR0pLYjJMUzhPNE51SlcwVGVZcm5DSFl1UGYwb0t2SmJlM0l6TC16TV8ydTNsZlRqanRhbUxsbk9maU82RVpiSmRzeg?oc=5","date":"2025-06-10","type":"trial","source":"globenewswire.com","summary":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights - globenewswire.com","headline":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQTG1ZUVUwWnAxYlhtMUNUaFlRVnVTajBPOERucExJbkpJR3Q0M1pLbjNwLU5hZWx6TmZlQ2dadkE0N2lMWi1ObENNcGtxTXhhU1gzTUx4cnhoamh6U1JFRVBJczdZWXFqa2ZKSjFid1FxNGpRR3J6Ym1CaGJRcXZHNlJTZTA3aHdURVhkR3BlM0gxUEdiZmFDak1hdUsxX08xYUZSSDV1REttUGxKelVLSmdXN3VvNjJYM0JRMjhKd3pvUFZFMWU0OXZIV2lnc0ZjYnZ4Z1J3MEFFRk4t?oc=5","date":"2025-03-14","type":"trial","source":"BioPharma APAC","summary":"BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial - BioPharma APAC","headline":"BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1xS1kyMzN6MEo2YnN3YjNId3VNRngzRUhucWhGOVpraVZyaTdtQmFjZldjTWFKcVlKUmRfdWlFNzB3RmRtODAxVndSejlXLWFmak1rR1hDVXdSM3lqYnJLcW85a1djTXFQbzlR?oc=5","date":"2025-03-14","type":"trial","source":"Clinical Trials Arena","summary":"BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial - Clinical Trials Arena","headline":"BioCity and MSD to evaluate cancer treatment combination in Phase I/II trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPMGgyOVR6WGlfOXpnX1VVUDluZ2tQZlpXQWUxRDhhR0tqMFBweVJtLXJGLTNha21sNDJfVV90X0k4Nm9EYThhQXhLM29RakNqMzJaTnQ1dFJTSzM2dUdFZDRrTURTaUoxanRrMlpwVVJrUGd6MGJ2SUJYWE9yRnNHbC1RWkZFZW9USzNJOHFwbXI0Y0h6SGJIbDlVbkY1VVJFaW13c3Bn?oc=5","date":"2024-07-09","type":"trial","source":"BioWorld News","summary":"Biocity’s SC-0062 hits endpoint in chronic kidney disease trial - BioWorld News","headline":"Biocity’s SC-0062 hits endpoint in chronic kidney disease trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQQnQ3ek9CQnFKc1ZucnRLT0owbkxpUFhRQi1YcGc2NW1HcGIwUFRGam11Vlg2X3BtSXlVVnFZLW4tYXdLajUyeUpyX0lJSDdQSUJrTlRSdGJ3N1RBcHpzeWFKdVBDRmdkUkNKSVNnbEhOS0U1SncxZkVkRGJkUGJxNVl3R3p0SzZYOVVHVTllYw?oc=5","date":"2024-04-10","type":"regulatory","source":"BioWorld News","summary":"FDA clears IND for Biocity Biopharma’s BC-2027 - BioWorld News","headline":"FDA clears IND for Biocity Biopharma’s BC-2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZUdOdk9PeU9KcHI2YVFKOVZxckVoclpnaW9PNGc1aEpWb1dtdjB6VVVZbXl1dDVlRkx3QVVoU2MwRmxmT2E5S3JmRXNZMUtBUFVhS2hBVlJWTTRNX3MxSTlxbnZCQ3V6cUJjbzJneDZiaXlQNDVkRGZmc3o2QXhEd1hQWGw0NkQ5aGE3T1A4c2VtODh1enZjaHNYZV9OZ245LTFKWVRYTkxJeTJhNUI2S0JfVWN2T3Nm?oc=5","date":"2023-08-15","type":"pipeline","source":"BioWorld News","summary":"China’s Biocity expands to US with pipeline of bispecific antibodies and ADCs - BioWorld News","headline":"China’s Biocity expands to US with pipeline of bispecific antibodies and ADCs","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}